UCB is beefing up its gene therapy ops with back-to-back deals to buy a startup and sign up a university spinout for discovery work
Belgian pharma player UCB is adding AAV gene therapy programs to the R&D menu through a pair of deals struck in Europe and the US.
The Brussels-based company has acquired a fledgling gene therapy startup in nearby Leuven — Handl Therapeutics — that was launched by longtime Novartis vet Florent Gros, one of two companies he’s co-founded in the last 2 years. And UCB inked a separate research deal with University of Florida spinout Lacerta.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,700+ biopharma pros reading Endpoints daily — and it's free.